Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
Thursday on WRAL at 6: Violence against healthcare workers is surging! WRAL Investigates why the people caring for us fear for their lives at work
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Seres Therapeutics Inc
(NQ:
MCRB
)
0.7152
-0.0448 (-5.89%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Seres Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Seres Therapeutics' SER-155 Reduces Infection, GvHD In Animal Study
March 18, 2022
Seres Therapeutics Inc (NASDAQ: MCRB) will present preclinical findings at the European Bone Marrow Transplantation (EBMT) Annual Meeting.
Via
Benzinga
Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting
March 18, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Earnings Perspective: Return On Capital Employed
March 08, 2022
Seres Therapeutics (NASDAQ:MCRB) brought in sales totaling $7.22 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 173.3%, resulting in a...
Via
Benzinga
Seres Therapeutics: Q4 Earnings Insights
March 01, 2022
Seres Therapeutics (NASDAQ:MCRB) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement....
Via
Benzinga
Earnings Scheduled For March 1, 2022
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
Earnings Preview: Seres Therapeutics
February 28, 2022
Seres Therapeutics (NASDAQ:MCRB) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
Seres Therapeutics to Present at Chardan Metagenomics and Microbiome Medicines Summit
February 22, 2022
From
Seres Therapeutics
Via
Business Wire
Seres Therapeutics to Host Fourth Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on March 1, 2022
February 22, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer
February 08, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Host Virtual Investor Event Highlighting Opportunities for Microbiome Therapeutics in Infection Protection on January 31, 2022
January 24, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics' Oral Microbiome Candidate Shows Meaningful Improvements In Difficile Infection
January 20, 2022
Seres Therapeutics Inc (NASDAQ: MCRB) has announced the publication of data from Phase 3 ECOSPOR III study SER-109 for recurrent C. difficile infection (...
Via
Benzinga
New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection
January 19, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
January 19, 2022
Via
AB Newswire
Topics
Bonds
Stocks
Exposures
Debt Markets
US Equities
Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Posts Interim Microbiome Data Analysis From Failed Ulcerative Colitis Study
December 16, 2021
Seres Therapeutics Inc (NASDAQ: MCRB) announced preliminary microbiome data analyses from the Phase 2b ECO-RESET study of SER-287 in patients with mild-to-moderate...
Via
Benzinga
Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis
December 16, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Jim Cramer Shares His Thoughts On Novavax, ViacomCBS And More
December 06, 2021
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Seres Therapeutics, Inc. (NASDAQ:
Via
Benzinga
52 Biggest Movers From Yesterday
December 01, 2021
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland...
Via
Benzinga
Exposures
Product Safety
Why Shares of Seres Therapeutics Rose More Than 21% on Tuesday
November 30, 2021
The biotech stock announced it had enrolled its first patient in a trial for one of its therapies.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
35 Stocks Moving In Tuesday's Mid-Day Session
November 30, 2021
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares jumped 105.9% to $4.53. The FDA approved expanded labeling for Cumberland Pharmaceuticals’ Caldolor, an...
Via
Benzinga
Exposures
Product Safety
Seres Therapeutics Announces First Patient Enrolled in Phase 1b Study of SER-155, an Investigational Microbiome Therapeutic to Reduce the Risk of Antibiotic-Resistant Bacterial Infections and Graft-Versus-Host Disease (GvHD)
November 30, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
November 24, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Looking Into Seres Therapeutics's Return On Capital Employed
November 11, 2021
According to Benzinga Pro, during Q3, Seres Therapeutics (NASDAQ:MCRB) earned $68.41 million, a 242.09% increase from the preceding quarter. Seres Therapeutics also posted a total...
Via
Benzinga
Mid-Afternoon Market Update: Nasdaq Tumbles 300 Points; PubMatic Shares Gain After Q3 Results
November 10, 2021
Toward the end of trading Wednesday, the Dow traded down 0.67% to 36,075.12 while the NASDAQ fell 1.90% to 15,585.20. The S&P also fell, dropping 0.99% to 4,638.64. The U.S....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 10, 2021
Gainers Seres Therapeutics (NASDAQ:MCRB) shares moved upwards by 31.29% to $9.02 during Wednesday's regular session. Trading volume for this security as of 12:30 EST...
Via
Benzinga
76 Biggest Movers From Yesterday
November 11, 2021
Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share. RenovoRx, Inc. (NASDAQ: RNXT) shares...
Via
Benzinga
Topics
Initial Public Offering
Exposures
Securities Market
Mid-Morning Market Update: Markets Edge Lower; US Inflation Rate Increases To 6.2%
November 10, 2021
Following the market opening Wednesday, the Dow traded down 0.07% to 36,293.80 while the NASDAQ fell 0.23% to 15,850.04. The S&P also fell, dropping 0.05% to 4,682.75. The U.S...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 10, 2021
Gainers Valneva (NASDAQ:VALN) shares increased by 24.51% to $50.34 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6...
Via
Benzinga
Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates
November 10, 2021
From
Seres Therapeutics, Inc.
Via
Business Wire
Bacthera and Seres Therapeutics Collaborate for Commercial Manufacturing of SER-109, a Potential Treatment Against Recurrent C. difficile Infection
November 10, 2021
From
Seres Therapeutics
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.